Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC

Stock Information for Pyxis Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pyxis Oncology Inc.

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pyxis Oncology to Participate in September Investor and Industry Conferences
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.